180 Life Sciences Corp.
ATNF
$0.8599
-$0.0011-0.13%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 73.07% | -52.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 43.64% | -46.98% | |||
| Operating Income | -43.64% | 46.98% | |||
| Income Before Tax | -446.13% | -7,190.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -410.76% | -7,190.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -410.76% | -7,190.68% | |||
| EBIT | -43.64% | 46.98% | |||
| EBITDA | -44.21% | 47.05% | |||
| EPS Basic | -1,183.42% | -6,765.63% | |||
| Normalized Basic EPS | -204.13% | -464.34% | |||
| EPS Diluted | -1,183.42% | -8,632.00% | |||
| Normalized Diluted EPS | -204.13% | -464.34% | |||
| Average Basic Shares Outstanding | 14.41% | 6.69% | |||
| Average Diluted Shares Outstanding | 14.41% | 6.69% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||